Alterations in the Plasma Metabolome Associated With Maternal Smoking During the First Trimester and Foetal Growth
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Wadzanai Masvosva und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Pregnancy Trimester, First, Metabolome, Fetal Development, Smoking. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Finnish Ministry of Social Affairs and Health, Finnish Foundation for Alcohol Studies.
Abstract (Originalsprache)
Tobacco smoking during pregnancy has been associated with an increased risk of adverse outcomes like low birth weight. This study determined changes in the circulating metabolome linked to maternal smoking in the first trimester and correlated these changes to the growth of the foetus. The circulating metabolome was examined from first trimester plasma samples by non‐targeted (global) liquid chromatography mass spectrometry‐based metabolite profiling of 227 pregnant women (99 smokers and 117 non‐smokers) from the Kuopio Birth Cohort Study. Tobacco smoking was self‐reported through a questionnaire and verified with cotinine measurements from plasma samples. In summary, 64 significant differences were observed between the groups after correction for multiple testing e.g. in metabolites indicating endocrine disruption (e.g. dehydroepiandrosterone sulphate [DHEA‐S], VIP = 2.70, d = 0.68, p < 0.0001), metabolites associated with oxidative stress (e.g. bilirubin, VIP = 2.00, d = 0.50, p < 0.0001) and lipid metabolism (e.g. LysoPC 16:1, VIP = 2.07, d = 0.51, p < 0.0001). Some of these metabolites, e.g. DHEA‐S and bilirubin, correlated with low birth weight, and some, e.g. LysoPC 16:1, correlated with small head circumference at birth. In conclusion, maternal smoking during the first trimester of pregnancy was associated with an altered metabolite profile linked to endocrine disruption and increased oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
- Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
- Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland.
ORCID-Profile: Wadzanai Masvosva, Taija Voutilainen, Marko Lehtonen, Retu Haikonen, Seppo Auriola, Leea Keski-Nisula, Jaana Rysä, Olli Kärkkäinen
Förderung
- Finnish Ministry of Social Affairs and Health
- Finnish Foundation for Alcohol Studies
Zitieren
APA
Masvosva, W., Voutilainen, T., Lehtonen, M., Haikonen, R., Auriola, S., Keski-Nisula, L., Rysä, J., & Kärkkäinen, O. (2025). Alterations in the Plasma Metabolome Associated With Maternal Smoking During the First Trimester and Foetal Growth. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70037
Vancouver
Masvosva W, Voutilainen T, Lehtonen M, Haikonen R, Auriola S, Keski-Nisula L, et al. Alterations in the Plasma Metabolome Associated With Maternal Smoking During the First Trimester and Foetal Growth. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70037
BibTeX
@article{Masvosva2025,
author = {Masvosva, Wadzanai and Voutilainen, Taija and Lehtonen, Marko and Haikonen, Retu and Auriola, Seppo and Keski-Nisula, Leea and Rysä, Jaana and Kärkkäinen, Olli},
title = {Alterations in the Plasma Metabolome Associated With Maternal Smoking During the First Trimester and Foetal Growth},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70037}
}
EUVIMED